Skip to main navigation Skip to search Skip to main content

Importance of minimal residual disease in hairy cell leukemia: Monoclonal antibodies as a therapeutic strategy

Research output: Contribution to journal › Review article › peer-review

Abstract

With the use of nucleoside analogs as frontline therapy, the prognosis of hairy cell leukemia HCL has improved dramatically. Unfortunately, disease recurrence remains problematic. Eradication of minimal residual disease MRD persisting after therapy may further improve outcome. The evolution of available techniques used to assess MRD, and the potential incorporation of novel agents such as monoclonal antibodies MoAbs into the treatment armamentarium for HCL mandate that MRD analyses be performed concurrently with routine assessments of disease status. Herein, the available data regarding the prevalence and clinical relevance of MRD after therapy for HCL is reviewed.

Original languageEnglish (US)
Pages (from-to)27-31
Number of pages5
JournalLeukemia and Lymphoma
Volume50
Issue numberSUPPL. 1
DOIs
StatePublished - 2009

Keywords

  • Minimal residual disease
  • Prognosis
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Importance of minimal residual disease in hairy cell leukemia: Monoclonal antibodies as a therapeutic strategy'. Together they form a unique fingerprint.

Cite this